Cibinetide — an erythropoietin-derived tissue-protective peptide
Healing & repairEvidence: early clinicalInvestigational
Investigational. In clinical development, not approved. Material sold as a research chemical is not the trial drug. Educational only — not medical advice.
What it is
ARA-290 (cibinetide) is a small peptide derived from erythropoietin, engineered to keep EPO's tissue-protective effects without raising red blood cells.
Proposed mechanism
It activates the "innate repair receptor" (an EPOR/β-common-receptor complex) to reduce inflammation and support nerve/tissue repair — studied in neuropathic pain (e.g., sarcoidosis).1
State of the evidence
Early-phase human trials (neuropathic pain); not approved.
Regulatory & status
Investigational; not approved.
Reconstitution (reference only)
Lab-handling reference only — not a preparation or dosing instruction: 1.5 mL (150 units) reconstitution solution per 16 mg vial. See the reconstitution calculator for the arithmetic. This page does not provide dosing guidance.
For educational and research purposes only. This content is not medical advice. Compounds referenced are research use only and not intended to diagnose, treat, cure, or prevent any disease. Free Peptide University does not sell compounds.